Bladder cancer: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 1, 2005, Pages 4-34

  Montie, James E ^a   Bahnson, Robert R ^b   Cohen, Samuel M ^c   Drucker, Beverly ^d   Eisenberger, Mario A ^e   El Galley, Rizk ^f   Herr, Harry W ^d   Hudes, Gary R ^g   Kuzel, Timothy M ^h   Lange, Paul H ⁱ   Patterson, Anthony ^j   Pollack, Alan ^g   Richie, Jerome P ^k   Seigne, John ^l   Shipley, William U ^k   Small, Eric J ^m   Trump, Donald L ⁿ   Walther, Philip J ^o   Wilson, Timothy G ^p  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ SEATTLE CANCER CARE ALLIANCE   (United States)

^j UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^k Dana Farber/Partners CancerCare   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ ROSWELL PARK CANCER INSTITUTE   (United States)

^o DUKE CANCER INSTITUTE   (United States)

^p City of Hope Cancer Center   (United States)

more..

Author keywords

Bladder cancer; Chemotherapy; NCCN Clinical Practice Guidelines; Radiation therapy; Urology; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; PACLITAXEL; VINBLASTINE;

BLADDER CANCER; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL PRACTICE; CYSTECTOMY; FOLLOW UP; HISTOLOGY; HISTOPATHOLOGY; HUMAN; KIDNEY PELVIS TUMOR; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROSTATE CARCINOMA; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; URETER TUMOR; UROGENITAL TRACT TUMOR;

CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; HUMANS; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 33745217393     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Brodsky GL. Pathology of bladder carcinoma. Hematol Oncol Clin North Am 1992;6:59-80.
3. Kakizoe T, Matsumoto K, Andoh M, et al. Adenocarcinoma of urachus: Report of 7 cases and review of literature. Urology 1983;21:360-366.
4. Herr HW. Urachal carcinoma: The case for extended partial cystectomy. J Urol 1994;151:365-366.
5. Reuter V. Pathology of bladder cancer: Assessments of prognostic variables in response therapy. Semin Oncol 1990;17:524-532.
6. Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVita VT, Hellamn S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
7. Hall RR, Parmar MKB, Richards AB, et al. Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. Br Med J 1994;308:257-260.
8. Greene FL, Page DL, Fleming ID et al., eds. AJCC Cancer Staging Manual, 6th ed. ©AJCC. New York, Berlin, Heidelberg: Springer-Verlag;2002.
9. Epstein JI, Amen MD, Reuter UR, et al. The World Health Organization International Society of Urologic Pathology (ISUP) Consensus classification of urothelial (transitional cell) lesions, neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448.
10. Murphy WM. Classification of urothelial neoplasms; one, two, three, around we go. Urol Oncol 2001;6:69-71.
11. Smith JA, Labasky RF, Cockett K, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, Tl, and TlS). J Urol 1999;162:1697-1701.
12. Herr H, Sogni PC. Does early cystectomy improve survival of patients with high-risk superficial bladder tumors? J Urol 2001;166:1296-1299.
13. Tanimoto A, Yuasa Y, Imai Y, et al. Bladder tumor staging: Comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology 1992;185:741-747.
14. Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: Comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging. Radiology 1994;193:239-245.
15. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
16. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cis-platinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297-303.
17. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561-569.
18. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3:738-747.
19. Scher HI. Chemotherapy for invasive bladder cancer: Neoadjuvant versus adjuvant. Semin Oncol. 1990;17:555-565.
20. Kata EJ, Herr H. The role of transurethral resection for muscle invasive bladder carcinoma (abstract). J Urol 1993;149:316A.
21. Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. Urol Clin North Am 1993;19:701-711.
22. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol 1998;16:3576-3583.
23. Shipley WU, Kaufman DS, Zehr EM, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-67.
24. Rotman M, Aziz H. Concomitant continuous infusion chemotherapy and radiation. Cancer 1990;65:823-835.
25. Russell KJ, Boileau MA, Higano C, et al. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1990;19:693-699.
26. Russell KJ, Boileau MA, Ireton RC, et al. Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology 1988;167:845-848.
27. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-2157.
28. Orsatti M, Curotto A, Canobbio L, et al. Alternating chemoradiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33:173-178.
29. Zietman AL, Shipley WU, Kaufman DS, et al. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:1673-1677.
30. Sternberg CN, de Mulder PHM, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol No. 30924. J Clin Oncol 2001;19:2638-2646.
31. Lorusso V, Manzione L, de Vita F, et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A Phase II multicenter trial. J Urol 2000;164:53-56.
32. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;17:3068-3077.
33. Busch C, Hawes D, Johansson S, et al. In: Droller MJ, ed. Bladder Cancer, Current Diagnosis and Treatment. Totowa, NJ: Humana Press; 2001:149-182.
34. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC (International Agency for Research on Cancer) Press; 2004.
35. th series. Washington, D.C.: American Registry of Pathology; 2004.
36. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105-108.
37. Check W. Bladder biopsies in step with clinical side. CAP Today (College of American Pathologists) 2004;18:43-54.